Trial Profile

A double blind, placebo-controlled study assessing the efficacy and safety of BXCL501

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexmedetomidine (Primary)
Indications Agitation; Alzheimer's disease; Dementia
Focus Registrational; Therapeutic Use
Acronyms TRANQUILITY In-Care

Most Recent Events

14 Nov 2024 According to BioXcel Therapeutics media release, company received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with Alzheimer dementia.
19 Sep 2024 According to BioXcel Therapeutics media release, company submitted its protocol for the TRANQUILITY In-Care trial to the U.S. Food and Drug Administration (FDA) on September 5, 2024.
11 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com